FY2026 EPS Estimates for Aytu BioPharma Cut by Analyst

Aytu BioPharma Inc. (NASDAQ:AYTU) – Ascendiant Capital Markets lowered their FY2026 earnings per share (EPS) estimates for Aytu BioPharma in a research note issued on Wednesday, June 10th. Ascendiant Capital Markets analyst E. Woo now anticipates that the company will earn ($0.73) per share for the year, down from their prior forecast of ($0.69). Ascendiant Capital Markets has a “Buy” rating and a $14.50 price objective on the stock. The consensus estimate for Aytu BioPharma’s current full-year earnings is ($0.73) per share. Ascendiant Capital Markets also issued estimates for Aytu BioPharma’s Q4 2026 earnings at ($0.22) EPS, Q1 2027 earnings at ($0.01) EPS, Q2 2027 earnings at $0.02 EPS and Q3 2027 earnings at $0.08 EPS.

Aytu BioPharma (NASDAQ:AYTU) last posted its earnings results on Wednesday, May 13th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.09). Aytu BioPharma had a negative return on equity of 69.93% and a negative net margin of 60.17%.The company had revenue of $12.41 million for the quarter, compared to analysts’ expectations of $12.05 million.

Several other brokerages have also commented on AYTU. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aytu BioPharma in a report on Wednesday, April 8th. Zacks Research raised Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $9.83.

Aytu BioPharma Stock Performance

Shares of AYTU opened at $2.15 on Monday. Aytu BioPharma has a 12 month low of $1.65 and a 12 month high of $3.07. The stock has a fifty day moving average price of $2.39 and a 200-day moving average price of $2.46. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 0.27. The firm has a market cap of $23.07 million, a PE ratio of -0.47 and a beta of 0.25.

Institutional Investors Weigh In On Aytu BioPharma

Several hedge funds have recently modified their holdings of AYTU. Daytona Street Capital LLC purchased a new position in Aytu BioPharma in the 4th quarter valued at about $26,000. Rothschild Wealth LLC purchased a new stake in shares of Aytu BioPharma during the 4th quarter worth $52,000. Dimensional Fund Advisors LP purchased a new stake in shares of Aytu BioPharma during the 3rd quarter worth $58,000. Bellevue Asset Management LLC purchased a new stake in shares of Aytu BioPharma during the 4th quarter worth $65,000. Finally, XTX Topco Ltd purchased a new stake in shares of Aytu BioPharma during the 4th quarter worth $67,000. 33.49% of the stock is owned by hedge funds and other institutional investors.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.